![Esperanza B. Papadopoulos, MD -- Clinical Director, Adult Bone Marrow Transplantation Inpatient Unit](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/477/image/papadopoulos-esperanza.jpg?h=10d202d3)
Esperanza B. Papadopoulos, MD
Bone Marrow Transplant Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Allogoeneic Hematopoietic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Bone Marrow Failure Syndromes
- Cellular Immunotherapy for Treatment of Post-Transplant Infectious Complications and Relapse
Request an Appointment
About Me
- Clinical Director, Adult Bone Marrow Transplantation Inpatient Unit
- Associate Vice Chair of Hospital Medicine Inpatient Operations, Department of Medicine
I am a board-certified hematologist and oncologist and work as a bone marrow and stem cell transplant physician on the Adult Bone Marrow Transplant Service. I am part of a multidisciplinary team that treats patients using stem cell transplantation to treat a variety of hematologic malignancies. My particular expertise is in the area of allogeneic transplantation — the use of stem cells or bone marrow derived from a donor other than the patient. Stem cells can come from different sources (related or unrelated donors, bone marrow, peripheral blood, or umbilical cord blood units) and be modified in different ways before transplantation. My current focus is risk stratification — determining which type of transplant is best for each patient who is able to undergo and benefit from an allogeneic transplant.
Read more
I am involved in a number of studies designed to find ways to lower the risk of graft-versus-host disease, a serious complication that can follow allogeneic transplantation. In one approach we are developing techniques to separate out the specific cells that evoke this response, the T lymphocytes, and deliver a stem cell product that is very low in these T cells. These approaches are more useful for patients whose acute leukemia or myelodysplastic syndrome is in an early stage of their disease. I am also studying the use of allogeneic stem cell transplants for the treatment of patients with more-advanced leukemia or myelodysplastic syndrome. Along with colleagues here, I am participating in studies of different combination chemotherapy regimens for patients with advanced or refractory acute leukemia. My practice consists of patients with a variety of hematologic malignancies who are in need of an allogeneic transplant, including patients with acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. The goal of my practice and clinical research is to be able to offer every patient in need of a transplant the opportunity to undergo this potentially curative therapy.
As Clinical Director of Memorial Sloan Kettering’s adult Bone Marrow Transplantation Inpatient Service, I lead a dedicated team of doctors and nurse specialists who care for patients undergoing transplantation during their stay in the hospital.
A bone marrow transplant specialist is a doctor with special training in bone marrow transplants.
My Specialties
- Allogoeneic Hematopoietic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Bone Marrow Failure Syndromes
- Cellular Immunotherapy for Treatment of Post-Transplant Infectious Complications and Relapse
Education
- MD, New York University School of Medicine
Residencies
- New York University Medical Center/Bellevue Hospital
Fellowships
- New York University Medical Center
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Papadopoulos sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Papadopoulos
- A Phase 1B/3 Study of Orca-T in People With Blood Cancers
- A Phase I Study of VOR33 Cellular Therapy and Mylotarg in People with Acute Myeloid Leukemia at High Risk of Relapse after Stem Cell Transplantation
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Papadopoulos’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Esperanza B. Papadopoulos discloses the following relationships and financial interests:
-
Biogen Idec
Equity -
Exelixis
Equity
-
Regulus Therapeutics
Equity
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].